1402p -13.0 -0.9%
Last Trade - 14/05/21
| Market Cap | £3.18bn |
| Enterprise Value | £3.08bn |
| Revenue | £269.3m |
| Position in Universe | 240th / 1826 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 144 | 171.7 | 217.1 | 233.2 | 259.9 | 260 | 317.5 | 343.1 | +12.5% | ||
| +10.0 | +10.0 | +7.4 | +84.8 | -15.4 | -31.5 | -21.6 | +26.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Abcam plc is a global life sciences company. The Company identifies, develops, and provides biological reagents and tools, which are required in a range of fields and applications including drug discovery, diagnostics and basic research. The Company’s solutions include research use only (RUO) proteomic tools and antibody development for clinical application. The RUO proteomic products include protein binding reagents, such as antibodies and immunoassays, and related reagents. The Company’s products are used by researchers to study biological pathways, which is critical for scientific research, diagnostics and drug discovery. The Company serves scientists and researchers in academic institutions, research institutes and pharmaceutical, biotechnology and diagnostics companies.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | February 12, 1998 |
| Public Since | November 3, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | 1,500 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 226,742,614 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Discovery Drive,Cambridge Biomedical Campus Hills Road, CAMBRIDGE, CB20AX, United Kingdom |
| Web | http://www.abcam.com/ |
| Phone | +44 1223 696000 |
| Contact | James Staveley (Vice President - Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 14/05/21, shares in Abcam are trading at 1402p, giving the company a market capitalisation of £3.18bn. This share price information is delayed by 15 minutes.
Shares in Abcam are currently trading at 1402p and the price has moved by 0.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abcam price has moved by -19.14% over the past year.
Of the analysts with advisory recommendations for Abcam, there are there are currently 0 "buy" , 7 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Abcam is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Abcam is scheduled to issue upcoming financial results on the following dates:
Abcam does not currently pay a dividend.
Abcam does not currently pay a dividend.
Abcam does not currently pay a dividend.
To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Abcam are currently trading at 1402p, giving the company a market capitalisation of £3.18bn.
Here are the trading details for Abcam:
Based on an overall assessment of its quality, value and momentum, Abcam is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Abcam are currently priced at 1402p. At that level they are trading at 0.21% premium to the analyst consensus target price of 1,399.06.
Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of 0.18581 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, the relative strength of its shares against the market has been -9.26%. At the current price of 1402p, shares in Abcam are trading at -2.78% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abcam PE ratio based on its reported earnings over the past 12 months is 96.28. The shares are currently trading at 1402p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abcam's management team is headed by:
Here are the top five shareholders of Abcam based on the size of their shareholding:
